Today: 20 November 2025
Subscribe
Browse Tag

Metsera

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race. 1. Where the Metsera–Pfizer Deal Stands Today Pfizer formally closed its acquisition of Metsera on November 13, 2025, after Metsera shareholders approved a sweetened offer that values the obesity biotech at up to $10 billion. Reuters+1 Key terms
17 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date: November 14, 2025Ticker: MTSR (Metsera, Inc.) – now being delisted On Friday, November 14, 2025, Metsera, Inc. officially disappears from the Nasdaq tape. Trading in Metsera (NASDAQ: MTSR) has been suspended after Pfizer completed its acquisition of the obesity-focused biotech in a deal valued at up to $10 billion, capping one of the fiercest pharma bidding wars of the year.
14 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock Today, November 12, 2025: Shares Nudge Higher as Jefferies Webcast Set, Metsera Deal Stays in Focus

Updated November 12, 2025 Pfizer’s stock is modestly higher in Wednesday trading. Around 2:00 p.m. ET, PFE changed hands near $25.94, up about 1.7% on the day. Earlier prints showed an intraday range of $25.25–$25.95 versus Tuesday’s close at $25.51. Bloomberg+2MarketWatch+2 What’s moving Pfizer today Pfizer schedules CFO appearance at Jefferies London Healthcare Conference (webcast).This morning the company invited investors to a live webcast with CFO Dave Denton on Wednesday, November 19, 2025 (9:00 a.m. GMT)—a near‑term catalyst where guidance framing, cost discipline, and integration priorities typically get airtime. A replay will be posted within 24 hours. Pfizer Media/market chatter
12 November 2025
 ·  ·  ·  ·  · 
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final deal structure. Key takeaways (Nov. 10) What changed today The revised terms, line by line (from today’s 8‑K) Metsera’s Form 8‑K filed this morning lays out material changes versus the September agreement: Why Novo bowed out — and the FTC’s
10 November 2025
 ·  ·  ·  ·  ·  ·  · 
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera (NASDAQ: MTSR) and Pfizer struck an amended deal worth up to $10B after Novo Nordisk exited the bidding. Here are the final terms, key dates, and what investors should watch next. Updated: November 8, 2025 Top takeaways What changed on Nov. 7–8 Friday, Nov. 7: Metsera announced an amended merger agreement with Pfizer at $86.25 per share (comprised of $65.60 per share in cash and a contingent value right of up to $20.65). The board unanimously reaffirmed its support for Pfizer’s deal, citing both superior certainty of closing and “unacceptably high legal and regulatory risk” tied to Novo’s competing
8 November 2025
 ·  ·  ·  · 
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Key takeaways What happened (Nov. 7–8) Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right (CVR) of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks tied to its two‑step proposal. Metsera’s board said Pfizer’s amended agreement carries lower antitrust risk and recommended shareholders approve it at a Nov. 13 meeting. PR Newswire+1 Notably, Pfizer had already received early termination of the HSR waiting period from
8 November 2025
 ·  ·  ·  · 
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. (NYSE: PFE) has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters Key takeaways What happened today Pfizer’s final, sweetened bid prevailed after a week of public twists that included legal skirmishes and regulatory warnings. Metsera said the legal and regulatory risks tied to Novo’s proposal—flagged by the FTC—were “unacceptably high,” tipping the
8 November 2025
 ·  ·  ·  ·  ·  · 
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer sealed a deal to acquire Metsera for up to $10 billion, ending one of 2025’s fiercest pharma bidding wars and reshaping the obesity‑drug race. Below are the facts, context, and what’s next for MTSR shareholders and the GLP‑1 landscape. What happened today Pfizer won the contest for Metsera, agreeing to acquire the clinical‑stage obesity‑drug developer in a transaction valued at up to $10 billion. Metsera’s board cited legal and regulatory certainty in favoring Pfizer’s revised terms, while Novo Nordisk said it will not raise its competing proposal and is exiting the race. The merger is expected to close shortly
8 November 2025
 ·  ·  ·  ·  · 
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera Stock Overview and Recent Performance Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alone reuters.com reuters.com. The share price is now hovering in the low $70s reuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emerged prnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4 reuters.com – reflecting hundreds of percent in gains for early investors. This latest surge was directly tied to major
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Bidding War Sends Metsera Shares Higher Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash (about $4.9B) plus up to $22.50 in contingent payments sec.gov. Pfizer CEO Albert Bourla said this deal “propels Pfizer into this key therapeutic area” of obesity treatment sec.gov. Metsera CEO Whit Bernard called the deal “an excellent outcome for our shareholders” and praised the chance to “realize the promise of improved human health at scale” under Pfizer’s wing sec.gov. On Oct. 30, Novo Nordisk dramatically entered the fray with
30 October 2025
 ·  ·  ·  ·  ·  ·  · 
Go toTop